These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

874 related items for PubMed ID: 16368266

  • 1. Mechanism of action of memantine.
    Johnson JW, Kotermanski SE.
    Curr Opin Pharmacol; 2006 Feb; 6(1):61-7. PubMed ID: 16368266
    [Abstract] [Full Text] [Related]

  • 2. The chemical biology of clinically tolerated NMDA receptor antagonists.
    Chen HS, Lipton SA.
    J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
    [Abstract] [Full Text] [Related]

  • 3. Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors.
    Gilling KE, Jatzke C, Hechenberger M, Parsons CG.
    Neuropharmacology; 2009 Apr; 56(5):866-75. PubMed ID: 19371579
    [Abstract] [Full Text] [Related]

  • 4. Activation of brain histaminergic neurotransmission: a mechanism for cognitive effects of memantine in Alzheimer's disease.
    Motawaj M, Burban A, Davenas E, Arrang JM.
    J Pharmacol Exp Ther; 2011 Feb; 336(2):479-87. PubMed ID: 21057059
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological implications of two distinct mechanisms of interaction of memantine with N-methyl-D-aspartate-gated channels.
    Chen HS, Lipton SA.
    J Pharmacol Exp Ther; 2005 Sep; 314(3):961-71. PubMed ID: 15901795
    [Abstract] [Full Text] [Related]

  • 6. In vitro galantamine-memantine co-application: mechanism of beneficial action.
    Zhao X, Marszalec W, Toth PT, Huang J, Yeh JZ, Narahashi T.
    Neuropharmacology; 2006 Dec; 51(7-8):1181-91. PubMed ID: 17011596
    [Abstract] [Full Text] [Related]

  • 7. [New therapeutic possibilities with low-affinity NMDA receptor antagonists].
    Kornhuber J, Weller M.
    Nervenarzt; 1996 Jan; 67(1):77-82. PubMed ID: 8676993
    [Abstract] [Full Text] [Related]

  • 8. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
    Tanović A, Alfaro V.
    Rev Neurol; 1996 Jan; 42(10):607-16. PubMed ID: 16703529
    [Abstract] [Full Text] [Related]

  • 9. Alzheimer's disease and the glutamate NMDA receptor.
    Doraiswamy PM.
    Psychopharmacol Bull; 2003 Jan; 37(2):41-9. PubMed ID: 14566213
    [Abstract] [Full Text] [Related]

  • 10. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease.
    Geerts H, Grossberg GT.
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):8S-16S. PubMed ID: 16809810
    [Abstract] [Full Text] [Related]

  • 11. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence.
    Danysz W, Parsons CG.
    Int J Geriatr Psychiatry; 2003 Sep; 18(Suppl 1):S23-32. PubMed ID: 12973747
    [Abstract] [Full Text] [Related]

  • 12. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond.
    Lipton SA.
    Nat Rev Drug Discov; 2006 Feb; 5(2):160-70. PubMed ID: 16424917
    [Abstract] [Full Text] [Related]

  • 13. [Role of magnesium ions on the regulation of NMDA receptor--a pharmacopathology of memantine].
    Kato T.
    Clin Calcium; 2004 Aug; 14(8):76-80. PubMed ID: 15577101
    [Abstract] [Full Text] [Related]

  • 14. The NMDA receptor complex: a long and winding road to therapeutics.
    Wood PL.
    IDrugs; 2005 Mar; 8(3):229-35. PubMed ID: 15772895
    [Abstract] [Full Text] [Related]

  • 15. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
    Wenk GL.
    J Clin Psychiatry; 2006 Mar; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
    [Abstract] [Full Text] [Related]

  • 16. [Efficacy of memantine in the treatment of Alzheimer's disease].
    Molinuevo Guix JL, Lladó Plarrumaní A.
    Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
    [Abstract] [Full Text] [Related]

  • 17. [Ketamine inhibits n-methyl-d-aspartate (NMDA) receptor mediated acetylcholine release from rabbit caudate nucleus slices].
    Feuerstein TJ.
    Anaesthesist; 1994 Nov; 43 Suppl 2():S48-51. PubMed ID: 7840414
    [Abstract] [Full Text] [Related]

  • 18. Differences in degree of trapping of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block.
    Mealing GA, Lanthorn TH, Murray CL, Small DL, Morley P.
    J Pharmacol Exp Ther; 1999 Jan; 288(1):204-10. PubMed ID: 9862772
    [Abstract] [Full Text] [Related]

  • 19. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
    Lipton SA.
    Curr Alzheimer Res; 2005 Apr; 2(2):155-65. PubMed ID: 15974913
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.